DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Dr Reddys Share Price Live Updates: Dr. Reddys Trading Insights

Economic Times 3 hrs ago·4 Nov 2026, 3:12 am

Dr. Reddy's Laboratories is currently in the spotlight as investors closely monitor its trading activity and market movements. The company, a major player in the global pharmaceutical sector, is seeing heightened interest due to recent developments and market dynamics.

For investors, this focus is significant as it highlights potential shifts in the company's performance or strategic direction. Dr. Reddy's is known for its diverse portfolio, and any notable activity can influence its stock price and investor sentiment.

Moving forward, stakeholders should keep an eye on official announcements and market trends. Understanding the broader context of these updates will be key to gauging the impact on the company's future trajectory.